No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy
<p>Background: The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemoradiotherapy when compared to HPV-negative tumours. HPV infection is linked to alterations in DNA damage response prote...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Cancer Research UK
2017
|
| Summary: | <p>Background: The majority of anal cancers (84-95%) are driven by infection with human papillomavirus (HPV). HPV-positive tumours show significantly better responses to chemoradiotherapy when compared to HPV-negative tumours. HPV infection is linked to alterations in DNA damage response proteins, including MRE11. MRE11 is a potential predictive biomarker for response to radiotherapy in muscle-invasive bladder cancer and may hold predictive power in other cancers.</p><p> Methods: Using a previously reported cohort we evaluated the levels of MRE11 in anal cancer and assessed its predictive value in this disease.</p><p> Results: We found no association between the level of MRE11 and relapse-free survival following chemo-radiotherapy.</p><p> Conclusion: MRE11 has no predictive value in the analysis of relapse-free survival after chemoradiotherapy in anal cancer and does not add to the prognostic value of p16 and tumour infiltrating lymphocyte (TIL) scores. Further investigation into the role of DNA repair proteins in anal cancer is required.</p> |
|---|